Brief Article
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 28, 2011; 17(44): 4917-4921
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4917
Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma
Ji-Bin Liu, Fu-Lin Qiang, Jing Dong, Jin Cai, Shu-Hui Zhou, Min-Xin Shi, Ke-Ping Chen, Zhi-Bin Hu
Ji-Bin Liu, Ke-Ping Chen, Institute of Life Science, Jiangsu University, Zhenjiang 212013, Jiangsu Province, China
Ji-Bin Liu, Fu-Lin Qiang, Jin Cai, Min-Xin Shi, Nantong Tumor Hospital, Nantong 226361, Jiangsu Province, China
Jing Dong, Zhi-Bin Hu, Department of Epidemiology and Biostatistics, Ministry of Education Key Lab for Cancer, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Shu-Hui Zhou, School of Radiology and Public Health, Soochow University, Suzhou 215123, Jiangsu Province, China
Zhi-Bin Hu, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing 210029, Jiangsu Province, China
Author contributions: Liu JB and Qiang FL contributed equally to this work; Liu JB and Qiang FJ performed the majority of experiments; Liu JB, Qiang FJ, and Dong J provided vital reagents and analytical tools and edited the manuscript; Liu JB, Qiang FJ, Cai J, Zhou SH and Shi MX collected all the specimens for this work; Liu JB, Dong J, Chen KP, and Hu Z designed the study and wrote the manuscript.
Supported by Jiangsu University and Nantong Tumour Hospital
Correspondence to: Ke-Ping Chen, Professor, Institute of Life Science, Jiangsu University, Zhenjiang 212013, Jiangsu Province, China.
Telephone: +86-511-88791923 Fax: +86-511-88791923
Received: May 6, 2011
Revised: August 6, 2011
Accepted: August 13, 2011
Published online: November 28, 2011

AIM: To detect the effects of plasma DNA methylation of Wnt antagonists/inhibitors on recurrence of esophageal squamous cell carcinoma (ESCC).

METHODS: We used methylation-specific polymerase chain reaction to detect hypermethylation of the promoter of four Wnt antagonists/inhibitors (SFRP-1, WIF-1, DKK-3 and RUNX3) using DNA from the plasma of ESCC patients (n = 81) and analyzed the association between promoter hypermethylation of Wnt pathway modulator genes and the two-year recurrence of ESCC.

RESULTS: Hypermethylation of SFRP-1, DKK-3 and RUNX-3 was significantly associated with an increased risk of ESCC recurrence (P = 0.001, 0.003 and 0.001 for SFRP-1, DKK-3 and RUNX3, respectively). Patients carrying two to three methylated genes had a significantly elevated risk of recurrence compared with those not carrying methylated genes (odds ratio = 15.69, 95% confidential interval: 2.97-83). The area under the receiver operating characteristic curve (AUC) was 77.1 for ESCC recurrence prediction (sensitivity = 66.67 and specificity = 83.3). When combining methylated genes and the clinical stage, the AUC was 83.69, with a sensitivity of 76.19 and a specificity of 83.3.

CONCLUSION: The status of promoter hypermethylation of Wnt antagonists/inhibitors in plasma may serve as a non-invasive prognostic biomarker for ESCC.

Keywords: Plasma, Methylation, Esophageal Cancer, Recurrence